T-cell Acute Lymphoblastic Leukemia Clinical Trials

12 recruiting

T-cell Acute Lymphoblastic Leukemia Trials at a Glance

14 actively recruiting trials for t-cell acute lymphoblastic leukemia are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Houston, Philadelphia, and Shenzhen. Lead sponsors running t-cell acute lymphoblastic leukemia studies include Baylor College of Medicine, Beijing GoBroad Hospital, and Beijing Biotech.

Browse t-cell acute lymphoblastic leukemia trials by phase

Treatments under study

About T-cell Acute Lymphoblastic Leukemia Clinical Trials

Looking for clinical trials for T-cell Acute Lymphoblastic Leukemia? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new T-cell Acute Lymphoblastic Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about T-cell Acute Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
St. Jude Children's Research Hospital100 enrolled3 locationsNCT06390319
Recruiting
Phase 2

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Wugen, Inc.125 enrolled12 locationsNCT06514794
Recruiting
Phase 1

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid LeukemiaT-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic Lymphoma
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT05995028
Recruiting
Phase 1

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

T-cell Acute Lymphoblastic Leukemia
New York Medical College30 enrolled16 locationsNCT04972942
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

T-cell Acute Lymphoblastic Leukemia
Eastern Cooperative Oncology Group20 enrolled1 locationNCT05289687
Recruiting
Phase 2

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

T-cell Acute Lymphoblastic LeukemiaRecruiting
The First Affiliated Hospital of Soochow University28 enrolled1 locationNCT05376111
Recruiting
Phase 2

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

T-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
M.D. Anderson Cancer Center22 enrolled1 locationNCT06561074
Recruiting
Phase 1

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

T-cell Acute Lymphoblastic LeukemiaLymphoblastic T-Cell Lymphoma
OneChain Immunotherapeutics20 enrolled2 locationsNCT05679895
Recruiting
Phase 1

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Stephan Grupp MD PhD33 enrolled1 locationNCT06934382
Recruiting
Phase 1Phase 2

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies

T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital80 enrolled4 locationsNCT06316427
Recruiting
Phase 1

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-non-Hodgkin Lymphoma
Baylor College of Medicine27 enrolled2 locationsNCT03690011
Recruiting
Phase 1

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-non-Hodgkin Lymphoma
Baylor College of Medicine54 enrolled2 locationsNCT03081910
Recruiting
Phase 2

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

RelapseT-cell Acute Lymphoblastic LeukemiaALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine59 enrolled1 locationNCT06686108